Biohaven Pays $105m For Turbo Boost In Migraine Drug Review Race

Biohaven has acquired a priority review voucher from GW Pharma to accelerate the US review of rimegepant, its oral CGRP receptor antagonist for migraine. The firm is competing with Allergan and Lilly in a race to get the next oral treatment approved.

Rocket

Connecticut-based Biohaven Pharmaceutical Holding Co. Ltd. has paid $105m for a US FDA priority review voucher that it intends to use in the second quarter of 2019 to speed the regulatory review of its oral migraine candidate rimegepant. Use of the voucher could cut the review period from 10 to six months.

Since the use of a voucher to expedite a new drug application requires 90 days’ notice, it would appear that...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip